INTRODUCTION
============

Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of subacute, chronic, or acquired muscular disorders ([@nlaa006-B1]). These myopathies involve skeletal muscle as well as many other organs, such as the lungs, heart, joints and skin. IIM are classified into 5 categories: polymyositis (PM), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), sporadic inclusion body myositis (sIBM), and nonspecific myositis ([@nlaa006-B2]). Pathological analysis of skeletal muscle biopsies occupies an important element of IIM classification. In addition to histological patterns, there are more than 15 myositis-specific autoantibodies, some of which define homogenous groups of patients because they are important factors involved in the mechanism underlying their pathogenesis ([@nlaa006-B3], [@nlaa006-B4]). However, the association between myositis-specific autoantibodies and pathological manifestations is unclear, except for antiaminoacyl-tRNA synthetase antibodies (anti-ARS), including the antihistidyl-tRNA synthetase antibody, and DM-specific autoantibodies including antimelanoma differentiation-associated gene 5 (anti-MDA5), anti-240/218 kDa helicase family protein (anti-Mi-2), and antitranscriptional intermediary factor-1γ (anti-TIF-1γ). Anti-ARS antibodies were the most common myositis-specific autoantibodies with IIM ([@nlaa006-B3]). Anti-MDA5, anti-Mi-2, and anti-TIF1-γ antibodies are also highly associated with typical skin symptoms including heliotrope rash, Gottron's sign, and mechanic's hand ([@nlaa006-B6], [@nlaa006-B7]). IMNM is characterized by predominant muscle fiber necrosis and regeneration with little inflammation. IMNM is also frequently associated with antisignal recognition particle (anti-SRP) and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) autoantibodies ([@nlaa006-B8]). These 2 autoantibodies show almost the same clinical and pathological manifestations including proximal muscle weakness, a high serum CK value, and low incidence of skin lesions and interstitial pneumonia.

HMGCR is an endoplasmic reticulum residing enzyme catalyzing the rate-limiting step of cholesterol biosynthesis within the mevalonate pathway ([@nlaa006-B18]). It can be competitively inhibited by statins ([@nlaa006-B19]), which are widely used to lower cholesterol levels. Previous studies reported that statins induce apoptosis of Bcl-2-positive lymphoma cells ([@nlaa006-B20]). In recent years, it became evident that statins have pleiotropic immunological effects involving antigen-presenting cells and T cells ([@nlaa006-B21], [@nlaa006-B22]) and can even prevent tumor development and T-cell lymphomas ([@nlaa006-B23]). Statins also inhibit beta chemokine receptor 4 (CCR4) ([@nlaa006-B26]), which expresses in Th2 lymphocytes and is the key molecule of adult T-cell lymphoma and human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy ([@nlaa006-B27]). In contrast to statins, anti-HMGCR antibody has no previous reports revealing an association with lymphomas or pleiotropic immunomodulatory effects. As such, clarifying the clinical manifestation and lymphocytic profile of anti-HMGCR antibody could reveal characteristics of anti-HMGCR antibody-positive myopathy.

In this study, we retrospectively reviewed 94 patients with IIM by focusing on Bcl-2 and CCR4 expressions. Pathological analysis showed Bcl-2- and CCR4-positive inflammation and lymphocytic accumulations in patients with anti-HMGCR antibody-positive myopathy. These findings could distinguish anti-HMGCR myopathy from other IIMs.

MATERIALS AND METHODS
=====================

Patients
--------

We studied 94 patients with IIM including anti-HMGCR antibody-positive necrotizing myopathy (HMGCR, n = 19), anti-SRP antibody-positive necrotizing myopathy (SRP, n = 10), antisynthetase syndrome (n = 16), antimitochondria M2 antibody-positive myositis (AMA-M2, n = 7), IMNM except for without anti-HMGCR-, anti-SRP-, anti-ARS-, and anti-AMA-M2-antibodies (other IMNM, n = 6), DM (n = 10), PM (n = 12), and sIBM (n = 14). These patients were diagnosed according to the diagnostic criteria detailed in the following references ([@nlaa006-B2]). Evaluations of anti-HMGCR and anti-SRP antibodies were performed by Cosmic Corporation (Tokyo, Japan) using ELISA kits as previously reported ([@nlaa006-B13], [@nlaa006-B14]). A summary of the patients is described in [Table 1](#nlaa006-T1){ref-type="table"}.

###### 

Clinical Manifestations of Patients in This Study

                                 HMGCR              SRP               ARS             AMA-M2          Other IMNM            DM                PM              sIBM       p value
  ------------------------ ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- --------------- ---------
  n (M:F)                      19 (8:11)         10 (4:6)          16 (6:10)          7 (3:4)           6 (1:5)          10 (4:6)          12 (4:8)         14 (9:5)     0.632
  Age at onset (Y)            39.7 ± 23.0       59.2 ± 16.3       62.5 ± 10.0       57.3 ± 11.8       61.2 ± 14.7       54.9 ± 19.7       57.3 ± 19.0      67.0 ± 14.4   0.014
  Disease duration (M)       74.5 ± 102.9        4.5 ± 1.5         6.4 ± 5.4        16.6 ± 20.5       17.7 ± 23.2        3.8 ± 1.3        9.3 ± 16.3       11.6 ± 8.8    \<0.001
  Statin exposure               7 (39%)           4 (40%)           4 (25%)           2 (29%)           3 (50%)           1 (10%)           2 (17%)          4 (29%)     0.696
  Muscle weakness              17 (89%)          10 (100%)         13 (81%)          7 (100%)          6 (100%)           8 (80%)          12 (100%)        14 (100%)    0.228
  Myalgia                      11 (58%)           3 (30%)           3 (19%)           2 (29%)           0 (0%)            4 (40%)           1 (8%)           0 (0%)      0.004
  Skin lesion                  10 (53%)           0 (0%)            7 (44%)           0 (0%)            3 (50%)          10 (100%)          0 (0%)           0 (0%)      \<0.001
   Heliotrope eyelids           1 (5%)            0 (0%)            1 (6%)            0 (0%)            0 (0%)            7 (70%)           0 (0%)           0 (0%)      \<0.001
   Gottron's sign               1 (5%)            0 (0%)            5 (31%)           0 (0%)            2 (33%)           9 (90%)           0 (0%)           0 (0%)      \<0.001
   Mechanic hand                0 (0%)            0 (0%)            6 (38%)           0 (0%)            0 (0%)            4 (40%)           0 (0%)           0 (0%)      \<0.001
   Around neck and back        10 (53%)           0 (0%)            5 (31%)           0 (0%)            2 (33%)           9 (90%)           0 (0%)           0 (0%)      \<0.001
  Interstitial pneumonia        0 (0%)            3 (30%)          10 (63%)           0 (0%)            1 (17%)           5 (50%)           0 (0%)           0 (0%)      \<0.001
  CK (IU/L)                 3650.0 ± 3462.2   5007.4 ± 3068.6   3942.3 ± 4602.0   1990.1 ± 2653.9   2621.7 ± 2418.7   1449.5 ± 1327.5   2087.6 ± 1249.2   673.4 ± 489.4  \<0.001
  T-chol (mg/dL)             226.6 ± 56.3      257.7 ± 55.3      195.1 ± 37.0      197.6 ± 32.5      230.0 ± 47.1      216.3 ± 39.3      217.8 ± 52.7     218.1 ± 40.1   0.142
  HDL-C (mg/dL)               59.7 ± 15.2       64.2 ± 21.9       48.4 ± 17.7       47.3 ± 20.5       51.2 ± 14.8       55.0 ± 17.9       49.3 ± 12.6      59.5 ± 16.3   0.219
  LDL-C (mg/dL)              144.0 ± 43.7      167.8 ± 33.8      122.3 ± 31.3      114.0 ± 34.2      144.5 ± 38.8      136.2 ± 41.4      133.8 ± 37.7     129.4 ± 36.9   0.139
  HBV                              0              1 (10%)              0                 0                 0                 0                 0                0        0.283
  HCV                              0                 0                 0                 0                 0                 0                 0             2 (14%)     0.142
  HTLV1                            0                 0                 0                 0                 0                 0                 0             1 (7%)      0.611

HMGCR, anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive myopathy; SRP, antisignal recognition particle antibody-positive myopathy; ARS, antisynthetase syndrome; AMA-M2, antimitochondrial M2 antibody-positive myositis; Other IMNM, IMNM without anti-HMGCR-, anti-SRP, anti-ARS-, or AMA-M2 antibodies; DM, dermatomyositis; PM, polymyositis; sIBM, sporadic inclusion body myositis; CK, creatine kinase; T-chol, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HBV, hepatitis B virus; HCV, hepatitis C virus; HTLV-1, human T-cell leukemia virus type 1.

This study was approved by and performed under the guidelines of the ethics committees of the National Hospital Organization Kure Medical Center and Chugoku Cancer Center (No. 28--54) and Hiroshima University (eki-574).

Muscle and Skin Biopsies
------------------------

Muscle biopsies were performed for diagnostic purposes. Muscle biopsy specimens were frozen in liquid nitrogen-cooled isopentane for histochemistry and immunohistochemistry. Skin biopsies were also performed in patients whose skin lesions were found by our dermatologists. Skin biopsy specimens were fixed in 10% formalin and paraffin-embedded. Pathological diagnosis was confirmed by routine histochemistry and immunohistochemistry.

Immunohistochemistry
--------------------

For each sample, 8-μm serial transverse sections of muscle biopsy specimens and 6-μm serial sections of skin biopsy specimens were immunostained by using a Ventana BenchMark GX automated slide staining system (Ventana Medical Systems, Tucson, AZ) with mouse monoclonal antibodies, or by using an En-Vision system (Dako, Glostrup, Denmark) with a rabbit polyclonal antibody according to manufacturer instructions. The use of primary mouse monoclonal antibodies and rabbit polyclonal antibody are described in [Table 2](#nlaa006-T2){ref-type="table"}.

###### 

Antibodies Used in This Study

  Antibody   Clone        Epitope (Clone)                                                                                                                                                             Source                                Animal   Dilution
  ---------- ------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- -------- --------------
  Bcl-2      Monoclonal   A Synthetic peptide of human Bcl-2 protein. (100/D5)                                                                                                                        Leica, Milton Keynes, UK              Mouse    1:50
  CCR4       Polyclonal   chemokine (C-C motif) receptor 4 recombinant protein epitope signature tag (HPA031613)                                                                                      Sigma-Aldrich, St Louis, MO           Rabbit   1:100
  CD3        Monoclonal   Purified CD3εγδ/CD3ω(F7.2.38)                                                                                                                                               Novocastra, Newcastle upon Tyne, UK   Rabbit   1:400
  CD4        Monoclonal   Recombinant human CD4 (1F6)                                                                                                                                                 Dako, Glostrup, Denmark               Mouse    1:20
  CD8        Monoclonal   Synthetic peptide corresponding to the 13 C-terminal amino acids of cytoplasmic domain of human CD8 coupled to thyroglobulin (C8/144B).                                     Dako                                  Mouse    1:100
  CD20       Monoclonal   Human tonsil B cells (L26)                                                                                                                                                  Dako                                  Mouse    Ready to use
  CD45       Monoclonal   Isolated neoplastic cells from a case of T-cell lymphoma/leukemia (2B11) and human peripheral blood lymphocytes maintained in T-cell growth factor (PD7/26) (2B11+PD7/26)   Dako                                  Mouse    Ready to use
  Ki-67      Monoclonal   Human recombinant peptide corresponding to a 1002 bp Ki-67 cDNA fragment (MIB-1)                                                                                            Dako                                  Mouse    1:50
  α-SMA      Monoclonal   Synthetic peptide corresponding to N-terminal of human α-SMA                                                                                                                Nichirei Bioscience, Tokyo, Japan     Mouse    Ready to use

α-SMA, α-smooth muscle actin; Bcl-2, B-cell lymphoma 2; CCR4, beta chemokine receptor 4.

For assessment, 20 randomly selected areas of all sections were photographed at an original magnification of 200-fold by a Nikon Eclipse 80i (Nikon Instech Co. Ltd., Tokyo, Japan). For each photograph, the number of immunopositive lymphocytes were manually counted, and Bcl-2, CCR4 labeling indexes (the percentage of immunopositive lymphocytes among 500 lymphocytes in areas where the highest nuclear labeling is observed) were calculated by using a previously reported methodology ([@nlaa006-B28]).

Statistical Analysis
--------------------

All values were expressed as mean ± SD unless stated otherwise. Differences among means were analyzed with the Kruskal-Wallis test, Mann-Whitney test, Chi-square test, Pearson's correlation coefficient test, or 1-way analysis of variance by using Prism 6 software (GraphPad Software, La Jolla, CA).

RESULTS
=======

Anti-HMGCR Antibody-Positive Myopathy Showed Bcl-2- and CCR4-Positive Lymphocyte Infiltration and Lymphocytic Accumulations in Skeletal Muscle
----------------------------------------------------------------------------------------------------------------------------------------------

A summary of pathological findings is provided in [Table 3](#nlaa006-T3){ref-type="table"}. Muscle biopsy specimens of anti-HMGCR antibody-positive myopathy showed necrosis or regeneration, and lymphocyte infiltration to the perivascular area and endomysium as previously reported ([Fig. 1A](#nlaa006-F1){ref-type="fig"}) ([@nlaa006-B10], [@nlaa006-B13], [@nlaa006-B29]). Infiltrated lymphocytes were positive for T-cell markers including CD4 ([Fig. 1B](#nlaa006-F1){ref-type="fig"}) and CD8 ([Fig. 1C](#nlaa006-F1){ref-type="fig"}) and negative for B-cell marker CD20 ([Fig. 1D](#nlaa006-F1){ref-type="fig"}). These lymphocytes were diffusely expressed for Bcl-2 in the perivascular area ([Fig. 1E](#nlaa006-F1){ref-type="fig"}) and endomysium ([Fig. 1F](#nlaa006-F1){ref-type="fig"}). Regenerating fibers were also positive for Bcl-2 as previously reported ([@nlaa006-B30]). CCR4-positive lymphocytes were also observed ([Fig. 1G](#nlaa006-F1){ref-type="fig"}). In 5 cases with anti-HMGCR antibody-positive myopathy, lymphocytic accumulations were observed ([Fig. 1H](#nlaa006-F1){ref-type="fig"}). Lymphocytes of these accumulations were positive not only for T-cell marker CD3 ([Fig. 1I](#nlaa006-F1){ref-type="fig"}), but also for B-cell marker CD20 ([Fig. 1J](#nlaa006-F1){ref-type="fig"}). Both Bcl-2- and CCR4-positive lymphocytes existed in these accumulations ([Fig. 1K, L](#nlaa006-F1){ref-type="fig"}). There were no cells positive for α-smooth muscle actin (α-SMA) within these accumulations ([Fig. 1M](#nlaa006-F1){ref-type="fig"}).

![Pathological changes in anti-HMGCR antibody-positive necrotizing myopathy patients showing muscular Bcl-2-positive lymphocyte infiltration and lymphoid follicle-like structures. (**A**) Inflammatory cell infiltrates to the endomysium and perivascular areas. (**B, C**) CD4-positive/CD8-positive lymphocytes infiltrated to the perivascular area and endomysium. (**D**) CD20-positive lymphocytes were rarely observed in mild cases with anti-HMGCR antibody-positive myopathy. (**E**) Bcl-2-positive lymphocytes are observed in the perivascular area. (**F**) Bcl-2-positive lymphocytes infiltrate to endomysium. (**G**) CCR4-positive lymphocytes were scattered in both perimysium and endomysium. (**H**) Lymphocytic accumulations were scattered in severe cases with anti HMGCR antibody-positive myopathy. (**I, J**) Lymphocytes were positive for CD3 and CD20 in these accumulations. (**K**) Lymphocytes were positive for Bcl-2 in lymphocytic accumulations. (**L**) CCR4-positive lymphocytes were observed in both endomysium and lymphocytic accumulations. (**M**) α-SMA was negative. (**N**) Bcl-2 indexes in anti-HMGCR antibody-positive myopathy were significantly highest in each group. (**O**) CCR4 indexes were highest in anti-HMGCR antibody-positive myopathy cases (\*\*\*p \< 0.001). (A--G) Patient 12. (H--K, M) Patient 11. (L) Patient 18. Scale bar: 100 µm.](nlaa006f1){#nlaa006-F1}

###### 

Pathological Manifestations of Patients in This Study

                                        HMGCR                SRP           ARS         AMA-M2      Other IMNM        DM            PM           sIBM        p value   
  --------------------------- ------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ----------- ---------
  n (M:F)                             19 (8:11)           10 (4:6)      16 (6:10)      7 (3:4)       6 (1:5)      10 (4:6)      12 (4:8)      14 (9:5)       0.632    
  Age at onset (Y)                   39.7 ± 23.0         59.2 ± 16.3   62.5 ± 10.0   57.3 ± 11.8   61.2 ± 14.7   54.9 ± 19.7   57.3 ± 19.0   67.0 ± 14.4     0.014    
  Disease duration (M)              74.5 ± 102.9          4.5 ± 1.5     6.4 ± 5.4    16.6 ± 20.5   17.7 ± 23.2    3.8 ± 1.3    9.3 ± 16.3    11.6 ± 8.8     \<0.001   
  Bcl-2                        Endomysial infiltration    19 (100%)      1 (10%)       2 (13%)       1 (14%)       1 (17%)          0             0         8 (57%)   \<0.001
  Small endomysial hotspots            9 (50%)                0          2 (13%)          0          1 (17%)          0             0          8 (57%)      \<0.001   
  Perivascular cuffing                 5 (28%)                0          1 (6%)        5 (71%)          0          2 (20%)          0             0         \<0.001   
  Lymphocytic accumulations            5 (26%)                0             0             0             0             0             0             0         \<0.001   
  Index in muscle (%)                44.8 ± 7.2           0.6 ± 1.1     3.6 ± 4.9     8.9 ± 5.4     2.3 ± 2.1     2.7 ± 3.7        n/a        8.2 ± 5.6     \<0.001   
  Index in skin (%)                  46.9 ± 8.9              n/a        2.9 ± 1.8        n/a        4.7 ± 1.2     3.0 ± 1.8        n/a           n/a        \<0.001   
  CCR4                           Index in muscle (%)     30.8 ± 8.9     0.1 ± 0.3         0             0             0             0            n/a       3.4 ± 6.8  \<0.001
  Index of skin (%)                  11.3 ± 3.6              n/a            0            n/a            0             0            n/a           n/a        \<0.001   
  Ki-67                          Index in muscle (%)      2.2 ± 2.2     0.3 ± 0.7     0.7 ± 1.4     0.9 ± 1.2     0.3 ± 0.5     1.9 ± 1.0        n/a       2.1 ± 1.2  \<0.001
  Index in skin (%)                   8.0 ± 5.3              n/a        0.3 ± 0.5        n/a        0.7 ± 0.6     0.2 ± 0.4        n/a           n/a        \<0.001   
  TCR/IGH rearrangement                   0                   0             0             0             0             0             0             0          1.000    

HMGCR, anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive myopathy; SRP, antisignal recognition particle antibody-positive myopathy; ARS, antisynthetase syndrome; AMA-M2, antimitochondrial M2 antibody-positive myositis; Other IMNM, IMNM without anti-HMGCR-, anti-SRP, anti-ARS-, or AMA-M2 antibodies; DM, dermatomyositis; PM, polymyositis; sIBM, sporadic inclusion body myositis; Bcl-2, B-cell lymphoma 2; CCR4, beta chemokine receptor 4; Ki-67, nuclear protein; n/a, not applicable.

In other IIM patients except for sIBM, endomysial Bcl-2- or CCR4-positive lymphocyte infiltration was barely observed (p \< 0.001). About a half of sIBM patients showed focal endomysial Bcl-2-positive lymphocytes infiltrations and small hotspots ([Fig. 2A, B](#nlaa006-F2){ref-type="fig"}). However, muscle biopsy specimens of sIBM patients had no lymphocytic accumulations. In addition, a sIBM patient with HTLV-1 infection showed that almost all lymphocytes were positive for CCR4 ([Fig. 2C](#nlaa006-F2){ref-type="fig"}), which was similar to other HTLV-1-associated disorders ([@nlaa006-B27]). On the other hand, Bcl-2-positive perivascular cuffings were observed most frequently in perimysiums of patients with AMA-M2 ([Fig. 2D](#nlaa006-F2){ref-type="fig"}, p \< 0.001).

![Bcl-2 and CCR4 immunopositivity in muscle of other IIMs. (**A, B**) Focal endomysial Bcl-2- and CD45-positive lymphocytes infiltrations forming hotspot were observed, especially in sIBM cases. (**C**) The muscle biopsy specimen of sIBM patient with HTLV-1 infection showed aberrant CCR4-positive lymphocytes. (**D**) Bcl-2-positive perivascular cuffings were scattered most frequently in cases with antimitochondria M2 antibody-positive myositis. (**E**) Superficial perivascular dermatitis in cases without anti-HMGCR antibody. (**F**) CD45-positive lymphocytes infiltrated mainly in perivascular areas. (**G**) Bcl-2-positive lymphocytes are scattered. (**H**) CCR4-positive cells were not observed. Scale bar: 100 µm.](nlaa006f2){#nlaa006-F2}

The Bcl-2 indexes of anti-HMGCR myopathy patients were ∼45%, which were higher than those of other IIMs ([Fig. 1N](#nlaa006-F1){ref-type="fig"}, p \< 0.001). Endomysial Bcl-2-positive lymphocytes were more frequently observed in anti-HMGCR-positive myopathy cases than in other IIMs (p \< 0.001). CCR4-positive lymphocytes were also more frequently observed in anti-HMGCR myopathy than in other IIMs ([Fig. 1O](#nlaa006-F1){ref-type="fig"}, p \< 0.001). In addition, Bcl-2-positive lymphocytic accumulations were observed only in anti-HMGCR myopathy patients.

Bcl-2-Positive Lymphocytes Also Infiltrated the Skin of Anti-HMGCR Antibody-Positive Myopathy Patients
------------------------------------------------------------------------------------------------------

Skin biopsy specimens from anti-HMGCR myopathy patients showed superficial perivascular dermatitis ([Fig. 3A](#nlaa006-F3){ref-type="fig"}). Lymphocytes were positive for CD3 ([Fig. 3B](#nlaa006-F3){ref-type="fig"}) and negative for CD20 ([Fig. 3C](#nlaa006-F3){ref-type="fig"}). These lymphocytes also expressed Bcl-2 mainly in perivascular areas ([Fig. 3D](#nlaa006-F3){ref-type="fig"}). In patients with muscular lymphocytic accumulations, lymphocytes also formed lymphocytic accumulations such as follicular lymphoma in cutis ([Fig. 3E](#nlaa006-F3){ref-type="fig"}). These accumulations were positive diffusely for CD3 ([Fig. 3F](#nlaa006-F3){ref-type="fig"}) and CD20 ([Fig. 3G](#nlaa006-F3){ref-type="fig"}). Bcl-2-positive lymphocytes infiltrated diffusely to skin tissues, but not into the centers of lymphocytic accumulations ([Fig. 3H](#nlaa006-F3){ref-type="fig"}). CCR4-positive lymphocytes were scattered ([Fig. 3I](#nlaa006-F3){ref-type="fig"}). There were no cells positive for α-SMA in these accumulations except for blood vessels ([Fig. 3J](#nlaa006-F3){ref-type="fig"}). In contrast, Bcl-2- and CCR4-positive lymphocytes infiltrating dermis were barely observed in cases without the anti-HMGCR antibody ([Fig. 2E--H](#nlaa006-F2){ref-type="fig"}).

![Pathological changes in skin of anti-HMGCR antibody-positive necrotizing myopathy patients also showed Bcl-2-positive lymphocyte infiltration and lymphocytic accumulations. (**A**) Skin biopsy specimens show superficial perivascular dermatitis. (**B**) CD3-positive lymphocytes are observed in epidermis and dermis. (**C**) CD20-positive lymphocytes are not observed. (**D**) Lymphocytes infiltrating skin are positive for Bcl-2. (**E**) In severe cases, lymphocytic accumulations are observed in dermis. (**F, G**) CD3-positive/CD20-positive lymphocytes infiltrate to cutis including these accumulations. (**H**) Bcl-2-positive lymphocytes were diffusely observed in skin tissues including these accumulations. (**I**) CCR4-positive lymphocytes were also scattered. (**J**) α-SMA was negative except for vessels. (**K**) Bcl-2 indexes of skin in anti-HMGCR antibody-positive myopathy were significantly highest in each group (\*\*\*p \< 0.001). (**L**) CCR4-positive lymphocytes were observed only in anti-HMGCR antibody-positive myopathy (\*\*\*p \< 0.001). (**A--E**) Patient 14. (**F--J**) Patient 10. Scale Bars: (**A--E**) 100 µm, (**F--H, J**) 500 µm, (**I**) 50 µm.](nlaa006f3){#nlaa006-F3}

The Bcl-2 indexes of anti-HMGCR myopathy patients were ∼47%, which were higher than those of other IIMs (\<5%; [Fig. 3K](#nlaa006-F3){ref-type="fig"}, p \< 0.001). CCR4-positive lymphocytes were not observed in other IIMs ([Fig. 3L](#nlaa006-F3){ref-type="fig"}, p \< 0.001).

Serum Cholesterol Levels Were Not Higher in Anti-HMGCR Antibody-Positive Myopathy
---------------------------------------------------------------------------------

A summary of clinical characteristics is provided in [Table 1](#nlaa006-T1){ref-type="table"}. Statistical analysis revealed that there were no significant differences in levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), and statin exposures among all groups in this study ([Fig. 4A--C](#nlaa006-F4){ref-type="fig"}).

![Cholesterol levels and lymphoid follicle-like structures. (**A--C**) There were no significant differences in cholesterol levels in each group. (**D**) Anti-HMGCR antibody-positive myopathy patients with lymphocytic accumulations had higher levels of LDL cholesterol than patients without these accumulations (\*p = 0.01).](nlaa006f4){#nlaa006-F4}

Clinical characteristics of anti-HMGCR antibody-positive necrotizing myopathy patients are described in [Table 4](#nlaa006-T4){ref-type="table"}. Interestingly, anti-HMGCR myopathy patients with Bcl-2-positive lymphocytic accumulations had higher levels of LDL-C (p = 0.010) than patients without lymphocytic accumulations ([Fig. 4D](#nlaa006-F4){ref-type="fig"}). However, there were no significant differences in total cholesterol, HDL-C levels, statin exposures, age of the onset, disease duration until their diagnosis, and titers of anti-HMGCR antibody.

###### 

Baseline Characteristics of Patients with Anti-HMGCR Antibody-Positive Myopathy

  Patient                               1                 2          3        4           5           6       7       8       9         10         11      12      13          14         15         16             17         18      19    
  --------------------------- --------------------- ------------- -------- -------- -------------- ------- ------- ------- ------- ------------- ------- ------- ------- -------------- ------- ------------- -------------- ------- ------- ----
  Age at onset (Y)                     50                40          48       11          9          68       3      48       5         53         42      35      36          75          3         71             35         66      21    
  Sex                                   F                 M          F        F           F           F       M       M       M          F          F       F       M          M           M          F             F           F       F    
  Age at biopsy (Y)                    51                42          56       33          35         68       6      51      27         55         47      35      37          75         22         72             37         67      21    
  Duration (M)                         10                24          96      270         290          6      36      30      264        24         60       6       9          8          228        12             24         12       6    
  Statin exposure                       −            Pravastatin     −        −      Rosuvastatin     −       −       −       −     Pravastatin     −       −       −     Atorvastatin     −     Pravastatin   Rosuvastatin     −       −    
  Associated cancer                     −                 −          −        −           −           −       −       −       −          −          −       −       −      Esophagus       −          −             −           −       −    
  Muscle weakness                      \+                \+          \+       \+          \+         \+      \+       −      \+         \+         \+      \+       −          \+         \+         \+             \+         \+      \+    
  Myalgia                              \+                \+          \+       −           −           −       −      \+       −         \+         --      \+      \+          \+          −          −             \+         \+      \+    
  Skin lesion                           −                 −          −        −           −           −       −       −      \+         \+         \+      \+      \+          \+         \+         \+             −          \+      \+    
  Interstitial pneumonia                −                 −          −        −           −           −       −       −       −          −          −       −       −          −           −          −             −           −       −    
  CK (IU/L)                           6576              4754        611      3750        814        7816    1718     130    1786       8510       1849    4344     153        2186       2646       2947           2263       13919   2578   
  T-chol (mg/dL)                       162               163        200      196         213         192     178     241     182        381        304     165     189        269         223        244           284         262     249   
  HDL-C (mg/dL)                        42                64          61       70          63         75      46      69      49         79         70      60      75          40         49         51             92         52      34    
  LDL-C (mg/dL)                        102               87         124      112         116         106     113     148     115        254        216     89      114        190         173        168           153         163     170   
  antibody (IU/mL)                     3.2               1.6        3.2      1.1         2.3         1.6     1.6     1.6     1.6        2.6        2.7     1.1     1.5        1.8         1.2        1.8           1.5         2.2     2.2   
  HBV                                   −                 −          −        −           −           −       −       −       −          −          −       −       −          −           −          −             −           −       −    
  HCV                                   −                 −          −        −           −           −       −       −       −          −          −       −       −          −           −          −             −           −       −    
  HTLV-1                                −                 −          −        −           −           −       −       −       −          −          −       −       −          −           −          −             −           −       −    
  Biopsy site                        rt. VL            lt. BB      rt. BB   lt. BF      rt. RF      lt BB   lt VL   lt BB   lt BB      lt TB      lt BB   lt VL   lt VL      lt BB       lt BB      lt BB         lt BB       lt TB   lt VL  
  Bcl-2                        Index in muscle (%)       35          53       42          37         51      58      36      41         52         46      52      43          47         44         42             36         43      56     37
  Index in skin (%)                     −                 −          −        −           −           −       −       −       −         58         61      43      46          48         34         44             −           −      41    
  Small endomysial hotspots            \+                 −          −        −           −          \+       −       −       −         \+         \+      \+      \+          \+          −         \+             −          \+       −    
  Perivascular cuffing                  −                 −          −        −           −           −       −       −       −         \+         \+      \+      \+          −           −          −             −          \+       −    
  Lymphocytic accumulations             −                 −          −        −           −           −       −       −       −         \+         \+      \+       −          \+          −          −             −          \+       −    
  CCR4                         Index of muscle (%)       33          32       32          17         16      38      23      34         28         32      22      26          37         48         16             36         38      39     39
  Index of skin (%)                     −                 −          −        −           −           −       −       −       −          6         13       8       8          13         15         11             −                  16    
  Ki-67                        Index in muscle (%)        4          1        1           0           0       2       0       0          0          5       4       5          4           7          0             1           1       8     7
  Index in skin (%)                     −                 −          −        −           −           −       −       −       −         16         11       5       7          13          0          3             −           −       9    

HMGCR, anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase; Y, years; M, months; CK, creatine kinase; T-chol, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HBV, hepatitis B virus; HCV, hepatitis C virus; HTLV-1, human T-cell leukemia virus type 1; Bcl-2, B-cell lymphoma 2; CCR4, beta chemokine receptor 4; Ki-67, nuclear protein; rt., right; lt., left; VL, vastus lateralis; BB, biceps brachii; BF, biceps femoris; RF, rectus femoris; TB, triceps brachii.

DISCUSSION
==========

In this study comprising 19 patients with anti-HMGCR antibody-positive myopathy and 75 patients with other IIM, Bcl-2- and CCR4-positive lymphocyte infiltrations and Bcl-2-positive lymphocytic accumulations were more frequently observed in patients with anti-HMGCR antibody-positive myopathy than in patients with other IIMs. In addition, patients with Bcl-2-positive lymphocytic accumulations had higher levels of LDL-C than patients without these accumulations.

The obvious difference between anti-HMGCR antibody-positive and anti-SRP antibody-positive necrotizing myopathies has not been previously reported except for a sarcolemmal MAC deposition. In previous studies, sarcolemmal MAC deposition has been raised as a common pathological feature of anti-HMGCR IMNM and this is more commonly seen in anti-HMGCR IMNM patients than in those with anti-SRP ([@nlaa006-B13], [@nlaa006-B31]). In this study, we observed Bcl-2- and CCR4-positive lymphocyte infiltrations in skin and muscle of anti-HMGCR antibody-positive myopathy patients who had a higher Bcl-2 index than patients with other IIMs. In addition, we observed lymphocytic accumulations without dendritic cells stained with α-SMA in muscle and skin of anti-HMGCR antibody-positive myopathy patients, which suggested that lymphocytic accumulations might be lymphoid follicle-like structures. Previous studies revealed that lymphoid follicles were observed with a clear germinal center in DM, especially in clinically amyopathic DM with anti-MDA5 antibody ([@nlaa006-B32]), and Bcl-2-positive lymphocytes existed in the periphery of lymphoid follicles in DM ([@nlaa006-B34]). In this study, our series of anti-HMGCR myopathy also showed that Bcl-2- and CCR4-positive lymphocytes sometimes do not exist in the center of lymphocytic accumulations of affected muscle and skin. However, we could not describe the association between pathological findings and clinical manifestation. Further investigation is needed regarding the dermal manifestation and pathology of anti-HMGCR antibody-positive myopathy.

HMGCR is an endoplasmic reticulum residing enzyme catalyzing the rate-limiting step of cholesterol biosynthesis within the mevalonate pathway ([@nlaa006-B18]). It can be competitively inhibited by statins ([@nlaa006-B19]), which are widely used to lower cholesterol levels. Previous studies reported that statins induce apoptosis of Bcl-2-positive lymphoma cells ([@nlaa006-B20]). In recent years, it became evident that statins have pleiotropic immunological effects involving antigen-presenting cells and T cells ([@nlaa006-B21], [@nlaa006-B22]) and can even prevent tumor development and T-cell lymphomas ([@nlaa006-B23]). Statins also inhibit CCR4 ([@nlaa006-B26]), which expresses in Th2 lymphocytes and is the key molecule of adult T-cell lymphoma and HTLV-1-associated myelopathy ([@nlaa006-B27]). In contrast to statins, the role of anti-HMGCR antibody has not been confirmed. Previous studies suggested that anti-HMGCR antibody might trigger an immune reaction, which, in selected individuals, might result in the release of myotoxic cytokines (e.g. IL-1β) that enter the sarcolemma and cause cell lysis ([@nlaa006-B15], [@nlaa006-B35]). Skeletal muscle-specific HMGCR knockout mice were reported to have myopathy with elevated serum creatine kinase and necrosis, which is similar to IMNM clinically and pathologically, and can be rescued by oral mevalonic acid administration ([@nlaa006-B36]). Interestingly, these mice showed higher low-density lipoprotein receptor levels in response to HMGCR deficiency, but their cholesterol levels did not decrease. In our study, cholesterol levels were not decreased in patients with anti-HMGCR antibody-positive IMNM, and patients with hyperlipidemia showed lymphocytic accumulations. Our findings suggested that the effects of anti-HMGCR antibody were similar to that of HMGCR deficiency and that hyperlipidemia might act as one of the worsening factors associated with anti-HMGCR antibody-positive necrotizing myopathy.

In conclusion, patients with anti-HMGCR antibodies showed a pattern of Bcl-2- and CCR4-positive Th2 lymphocyte infiltration to endomysium and lymphocytic accumulations in their muscle and skin. Lymphocytic accumulations were associated with an increase in LDL cholesterol. Our study suggests that anti-HMGCR antibody is opposite to statins in regulating lymphocytes and causes specific pathological manifestations. We need further investigation of clinical manifestations of anti-HMGCR antibody-positive myopathy patients.
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